Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML). Gentil, M., Hugues, P., Desterke, C., Telliam, G., Sloma, I., Souza, L. E. B., Baykal, S., Artus, J., Griscelli, F., Guerci, A., Johnson-Ansah, H., Foudi, A., Bennaceur-Griscelli, A., & Turhan, A. G. PloS One, 13(8):e0200923, 2018. doi abstract bibtex Aryl Hydrocarbon Receptor (AHR) is an ubiquitous basic helix-loop-helix transcription factor, which is ligand-activated and involved in numerous biological processes including cell division, cell quiescence and inflammation. It has been shown that AHR is involved in normal hematopoietic progenitor proliferation in human cells. In addition, loss of AHR in knockout mice is accompanied by a myeloproliferative syndrome-like disease, suggesting a role of AHR in hematopoietic stem cell (HSC) maintenance. To study the potential role of AHR pathway in CML progenitors and stem cells, we have first evaluated the expression of AHR in UT-7 cell line expressing BCR-ABL. AHR expression was highly reduced in UT-7 cell expressing BCR-ABL as compared to controls. AHR transcript levels, quantified in primary peripheral blood CML cells at diagnosis (n = 31 patients) were found to be significantly reduced compared to healthy controls (n = 15). The use of StemRegenin (SR1), an AHR antagonist, induced a marked expansion of total leukemic cells and leukemic CD34+ cells by about 4- and 10-fold respectively. SR1-treated CML CD34+ cells generated more colony-forming cells and long-term culture initiating cell (LTC-IC)-derived progenitors as compared to non-SR1-treated counterparts. Conversely, treatment of CML CD34+ cells with FICZ, a natural agonist of AHR, induced a 3-fold decrease in the number of CD34+ cells in culture after 7 days. Moreover, a 4-day FICZ treatment was sufficient to significantly reduce the clonogenic potential of CML CD34+ cells and this effect was synergized by Imatinib and Dasatinib treatments. Similarly, a 3-day FICZ treatment contributed to hinder significantly the number of LTC-IC-derived progenitors without synergistic effect with Imatinib. The analysis of molecular circuitry of AHR signaling in CML showed a transcriptional signature in CML derived CD34+ CD38- primitive cells with either low or high levels of AHR, with an upregulation of myeloid genes involved in differentiation in the "AHR low" fraction and an upregulation of genes involved in stem cell maintenance in the "AHR high" fraction. In conclusion, these findings demonstrate for the first time that down-regulation of AHR expression, a major cell cycle regulator, is involved in the myeloproliferative phenotype associated with CML. AHR agonists inhibit clonogenic and LTC-IC-derived progenitor growth and they could be used in leukemic stem cell targeting in CML.
@article{gentil_aryl_2018,
title = {Aryl hydrocarbon receptor ({AHR}) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia ({CML})},
volume = {13},
issn = {1932-6203},
doi = {10.1371/journal.pone.0200923},
abstract = {Aryl Hydrocarbon Receptor (AHR) is an ubiquitous basic helix-loop-helix transcription factor, which is ligand-activated and involved in numerous biological processes including cell division, cell quiescence and inflammation. It has been shown that AHR is involved in normal hematopoietic progenitor proliferation in human cells. In addition, loss of AHR in knockout mice is accompanied by a myeloproliferative syndrome-like disease, suggesting a role of AHR in hematopoietic stem cell (HSC) maintenance. To study the potential role of AHR pathway in CML progenitors and stem cells, we have first evaluated the expression of AHR in UT-7 cell line expressing BCR-ABL. AHR expression was highly reduced in UT-7 cell expressing BCR-ABL as compared to controls. AHR transcript levels, quantified in primary peripheral blood CML cells at diagnosis (n = 31 patients) were found to be significantly reduced compared to healthy controls (n = 15). The use of StemRegenin (SR1), an AHR antagonist, induced a marked expansion of total leukemic cells and leukemic CD34+ cells by about 4- and 10-fold respectively. SR1-treated CML CD34+ cells generated more colony-forming cells and long-term culture initiating cell (LTC-IC)-derived progenitors as compared to non-SR1-treated counterparts. Conversely, treatment of CML CD34+ cells with FICZ, a natural agonist of AHR, induced a 3-fold decrease in the number of CD34+ cells in culture after 7 days. Moreover, a 4-day FICZ treatment was sufficient to significantly reduce the clonogenic potential of CML CD34+ cells and this effect was synergized by Imatinib and Dasatinib treatments. Similarly, a 3-day FICZ treatment contributed to hinder significantly the number of LTC-IC-derived progenitors without synergistic effect with Imatinib. The analysis of molecular circuitry of AHR signaling in CML showed a transcriptional signature in CML derived CD34+ CD38- primitive cells with either low or high levels of AHR, with an upregulation of myeloid genes involved in differentiation in the "AHR low" fraction and an upregulation of genes involved in stem cell maintenance in the "AHR high" fraction. In conclusion, these findings demonstrate for the first time that down-regulation of AHR expression, a major cell cycle regulator, is involved in the myeloproliferative phenotype associated with CML. AHR agonists inhibit clonogenic and LTC-IC-derived progenitor growth and they could be used in leukemic stem cell targeting in CML.},
language = {eng},
number = {8},
journal = {PloS One},
author = {Gentil, Melanie and Hugues, Patricia and Desterke, Christophe and Telliam, Gladys and Sloma, Ivan and Souza, Lucas E. B. and Baykal, Seda and Artus, Jerome and Griscelli, Frank and Guerci, Agnes and Johnson-Ansah, Hyacinthe and Foudi, Adlen and Bennaceur-Griscelli, Annelise and Turhan, Ali G.},
year = {2018},
pmid = {30091999},
pmcid = {PMC6084853},
pages = {e0200923},
}
Downloads: 0
{"_id":"dd2bADdo6EGQxiqmx","bibbaseid":"gentil-hugues-desterke-telliam-sloma-souza-baykal-artus-etal-arylhydrocarbonreceptorahrisanoveldruggablepathwaycontrollingmalignantprogenitorproliferationinchronicmyeloidleukemiacml-2018","author_short":["Gentil, M.","Hugues, P.","Desterke, C.","Telliam, G.","Sloma, I.","Souza, L. E. B.","Baykal, S.","Artus, J.","Griscelli, F.","Guerci, A.","Johnson-Ansah, H.","Foudi, A.","Bennaceur-Griscelli, A.","Turhan, A. G."],"bibdata":{"bibtype":"article","type":"article","title":"Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML)","volume":"13","issn":"1932-6203","doi":"10.1371/journal.pone.0200923","abstract":"Aryl Hydrocarbon Receptor (AHR) is an ubiquitous basic helix-loop-helix transcription factor, which is ligand-activated and involved in numerous biological processes including cell division, cell quiescence and inflammation. It has been shown that AHR is involved in normal hematopoietic progenitor proliferation in human cells. In addition, loss of AHR in knockout mice is accompanied by a myeloproliferative syndrome-like disease, suggesting a role of AHR in hematopoietic stem cell (HSC) maintenance. To study the potential role of AHR pathway in CML progenitors and stem cells, we have first evaluated the expression of AHR in UT-7 cell line expressing BCR-ABL. AHR expression was highly reduced in UT-7 cell expressing BCR-ABL as compared to controls. AHR transcript levels, quantified in primary peripheral blood CML cells at diagnosis (n = 31 patients) were found to be significantly reduced compared to healthy controls (n = 15). The use of StemRegenin (SR1), an AHR antagonist, induced a marked expansion of total leukemic cells and leukemic CD34+ cells by about 4- and 10-fold respectively. SR1-treated CML CD34+ cells generated more colony-forming cells and long-term culture initiating cell (LTC-IC)-derived progenitors as compared to non-SR1-treated counterparts. Conversely, treatment of CML CD34+ cells with FICZ, a natural agonist of AHR, induced a 3-fold decrease in the number of CD34+ cells in culture after 7 days. Moreover, a 4-day FICZ treatment was sufficient to significantly reduce the clonogenic potential of CML CD34+ cells and this effect was synergized by Imatinib and Dasatinib treatments. Similarly, a 3-day FICZ treatment contributed to hinder significantly the number of LTC-IC-derived progenitors without synergistic effect with Imatinib. The analysis of molecular circuitry of AHR signaling in CML showed a transcriptional signature in CML derived CD34+ CD38- primitive cells with either low or high levels of AHR, with an upregulation of myeloid genes involved in differentiation in the \"AHR low\" fraction and an upregulation of genes involved in stem cell maintenance in the \"AHR high\" fraction. In conclusion, these findings demonstrate for the first time that down-regulation of AHR expression, a major cell cycle regulator, is involved in the myeloproliferative phenotype associated with CML. AHR agonists inhibit clonogenic and LTC-IC-derived progenitor growth and they could be used in leukemic stem cell targeting in CML.","language":"eng","number":"8","journal":"PloS One","author":[{"propositions":[],"lastnames":["Gentil"],"firstnames":["Melanie"],"suffixes":[]},{"propositions":[],"lastnames":["Hugues"],"firstnames":["Patricia"],"suffixes":[]},{"propositions":[],"lastnames":["Desterke"],"firstnames":["Christophe"],"suffixes":[]},{"propositions":[],"lastnames":["Telliam"],"firstnames":["Gladys"],"suffixes":[]},{"propositions":[],"lastnames":["Sloma"],"firstnames":["Ivan"],"suffixes":[]},{"propositions":[],"lastnames":["Souza"],"firstnames":["Lucas","E.","B."],"suffixes":[]},{"propositions":[],"lastnames":["Baykal"],"firstnames":["Seda"],"suffixes":[]},{"propositions":[],"lastnames":["Artus"],"firstnames":["Jerome"],"suffixes":[]},{"propositions":[],"lastnames":["Griscelli"],"firstnames":["Frank"],"suffixes":[]},{"propositions":[],"lastnames":["Guerci"],"firstnames":["Agnes"],"suffixes":[]},{"propositions":[],"lastnames":["Johnson-Ansah"],"firstnames":["Hyacinthe"],"suffixes":[]},{"propositions":[],"lastnames":["Foudi"],"firstnames":["Adlen"],"suffixes":[]},{"propositions":[],"lastnames":["Bennaceur-Griscelli"],"firstnames":["Annelise"],"suffixes":[]},{"propositions":[],"lastnames":["Turhan"],"firstnames":["Ali","G."],"suffixes":[]}],"year":"2018","pmid":"30091999","pmcid":"PMC6084853","pages":"e0200923","bibtex":"@article{gentil_aryl_2018,\n\ttitle = {Aryl hydrocarbon receptor ({AHR}) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia ({CML})},\n\tvolume = {13},\n\tissn = {1932-6203},\n\tdoi = {10.1371/journal.pone.0200923},\n\tabstract = {Aryl Hydrocarbon Receptor (AHR) is an ubiquitous basic helix-loop-helix transcription factor, which is ligand-activated and involved in numerous biological processes including cell division, cell quiescence and inflammation. It has been shown that AHR is involved in normal hematopoietic progenitor proliferation in human cells. In addition, loss of AHR in knockout mice is accompanied by a myeloproliferative syndrome-like disease, suggesting a role of AHR in hematopoietic stem cell (HSC) maintenance. To study the potential role of AHR pathway in CML progenitors and stem cells, we have first evaluated the expression of AHR in UT-7 cell line expressing BCR-ABL. AHR expression was highly reduced in UT-7 cell expressing BCR-ABL as compared to controls. AHR transcript levels, quantified in primary peripheral blood CML cells at diagnosis (n = 31 patients) were found to be significantly reduced compared to healthy controls (n = 15). The use of StemRegenin (SR1), an AHR antagonist, induced a marked expansion of total leukemic cells and leukemic CD34+ cells by about 4- and 10-fold respectively. SR1-treated CML CD34+ cells generated more colony-forming cells and long-term culture initiating cell (LTC-IC)-derived progenitors as compared to non-SR1-treated counterparts. Conversely, treatment of CML CD34+ cells with FICZ, a natural agonist of AHR, induced a 3-fold decrease in the number of CD34+ cells in culture after 7 days. Moreover, a 4-day FICZ treatment was sufficient to significantly reduce the clonogenic potential of CML CD34+ cells and this effect was synergized by Imatinib and Dasatinib treatments. Similarly, a 3-day FICZ treatment contributed to hinder significantly the number of LTC-IC-derived progenitors without synergistic effect with Imatinib. The analysis of molecular circuitry of AHR signaling in CML showed a transcriptional signature in CML derived CD34+ CD38- primitive cells with either low or high levels of AHR, with an upregulation of myeloid genes involved in differentiation in the \"AHR low\" fraction and an upregulation of genes involved in stem cell maintenance in the \"AHR high\" fraction. In conclusion, these findings demonstrate for the first time that down-regulation of AHR expression, a major cell cycle regulator, is involved in the myeloproliferative phenotype associated with CML. AHR agonists inhibit clonogenic and LTC-IC-derived progenitor growth and they could be used in leukemic stem cell targeting in CML.},\n\tlanguage = {eng},\n\tnumber = {8},\n\tjournal = {PloS One},\n\tauthor = {Gentil, Melanie and Hugues, Patricia and Desterke, Christophe and Telliam, Gladys and Sloma, Ivan and Souza, Lucas E. B. and Baykal, Seda and Artus, Jerome and Griscelli, Frank and Guerci, Agnes and Johnson-Ansah, Hyacinthe and Foudi, Adlen and Bennaceur-Griscelli, Annelise and Turhan, Ali G.},\n\tyear = {2018},\n\tpmid = {30091999},\n\tpmcid = {PMC6084853},\n\tpages = {e0200923},\n}\n\n","author_short":["Gentil, M.","Hugues, P.","Desterke, C.","Telliam, G.","Sloma, I.","Souza, L. E. B.","Baykal, S.","Artus, J.","Griscelli, F.","Guerci, A.","Johnson-Ansah, H.","Foudi, A.","Bennaceur-Griscelli, A.","Turhan, A. G."],"key":"gentil_aryl_2018","id":"gentil_aryl_2018","bibbaseid":"gentil-hugues-desterke-telliam-sloma-souza-baykal-artus-etal-arylhydrocarbonreceptorahrisanoveldruggablepathwaycontrollingmalignantprogenitorproliferationinchronicmyeloidleukemiacml-2018","role":"author","urls":{},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"http://bibbase.org/zotero/biblioial","dataSources":["ftoP3zPyb2N3b9Noc"],"keywords":[],"search_terms":["aryl","hydrocarbon","receptor","ahr","novel","druggable","pathway","controlling","malignant","progenitor","proliferation","chronic","myeloid","leukemia","cml","gentil","hugues","desterke","telliam","sloma","souza","baykal","artus","griscelli","guerci","johnson-ansah","foudi","bennaceur-griscelli","turhan"],"title":"Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML)","year":2018}